- 2025-11-19
(19 November 2025, Shanghai, China) Recently, the World Health Organization (WHO) awarded prequalification to two child-friendly formulations of primaquine, which was independently developed by Guilin Pharmaceutical Co., Ltd., a subsidiary of Fosun Pharma. These are the first pediatric formulations of primaquine phosphate prequalified by WHO. The products are intended for the most vulnerable group, which is also the most susceptible to repeated malaria infections, and will provide more suitable and accessible treatment options for young malaria patients globally.
- 2025-08-18
(August 18, 2025, Shanghai, China）— On August 18, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; SSE: 600196, HKEX: 02196) announced that its self-developed innovative drug Luvometinib Tablets (Chinese trade name: 复迈宁®; the “Drug”) has gained Breakthrough Therapy Designation by the Saudi Food and Drug Authority (SFDA) for the treatment of adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms. This milestone marks the acceleration of the Drug’s registration and commercialization process in Saudi Arabia.
- 2025-07-17
On July 17, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) announced that S-INFINITY Co., Ltd. (“S-INFINITY”), a subsidiary of Fosun Pharma, has recently initiated the Phase 1b clinical trial on its self-developed new drug, XH-S004 (hereinafter the “New Drug”), for the treatment of chronic obstructive pulmonary disease (COPD) in China (excluding Hong Kong SAR, Macau SAR, and Taiwan region).
- 2025-07-09
(July 9, 2025, Shanghai, China）— On 9 July, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; Stock Code: 600196.SH, 02196.HK), announced that its self-developed MEK1/2 selective inhibitor Fu Mai Ning (generic name: Luvometinib Tablets; the “Drug”) has entered Phase 3 clinical trial for the treatment of pediatric low-grade glioma (pLGG) in China (excluding Hong Kong SAR, Macau SAR and Taiwan region).
- 2025-06-04
The updated data of efficacy and safety of Luvometinib (FCN-159), a self-developed innovative drug by Fosun Pharma, in pediatric participants with neurofibromatosis type 1 from a phase 2 study was presented in the American Society of Clinical Oncology (ASCO) Annual Meeting on May 22, 2025
- 2025-05-29
(May 29, 2025, Shanghai, China） — On 29 May, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; Stock Code: 600196.SH, 02196.HK), announced that its self-developed innovative drug Luvometinib Tablets (Chinese trade name: 复迈宁®, project no.: FCN-159, the “New Drug”) has been officially approved for marketing by the National Medical Products Administration (NMPA).
- 2021-10-28
Chinese pharmaceutical companies are turning their attention to innovation, shifting rapidly from mastery of follow-on drugs to researching first-in-class and best-in-class drugs. Aiming to be a healthcare group with a global presence, Fosun Pharma, established in Shanghai in 1994, has built its core business around innovative drug R&D and manufacturing.
- 2021-10-07
On November 6, 2021, as a parallel supporting event of the 4th China International Import Expo (CIIE), the 4th Hongqiao International Health Technology Innovation Forum with the theme of "Innovation for Good Health" was successfully held. This forum was sponsored by the International Health Exchange and Cooperation Center NHC PRC (IHECC) and China Pharmaceutical Innovation and Research Development Association,
- 2021-09-28
In this meeting, Henlius releases phase 2 study results of serplulimab (HLX10, novel anti-PD-1 antibody), in patients with advanced cervical cancer in an oral presentation.
- 2021-09-28
In this meeting, Henlius releases phase 3 study results of HLX04 (bevacizumab biosimilar), in patients with metastatic colorectal cancer in an oral presentation.
